-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

Benzinga·07/21/2026 13:57:49
語音播報
Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.